isabelle fournier
INSERM U1192 Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM)
Villeneuve-d'Ascq, France
Review Editor
Molecular Medicine and Cancer Treatment
INSERM U1192 Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM)
Villeneuve-d'Ascq, France
Review Editor
Molecular Medicine and Cancer Treatment
Xiangya Hospital, Central South University
Changsha, China
Review Editor
Molecular Medicine and Cancer Treatment
University of Illinois Chicago
Chicago, United States
Review Editor
Molecular Medicine and Cancer Treatment
University of Bristol
Bristol, United Kingdom
Review Editor
Molecular Medicine and Cancer Treatment
University of Galway
Galway, Ireland
Review Editor
Molecular Medicine and Cancer Treatment
Institute of Molecular Biology and Biophysics FRC FTM
Novosibirsk, Russia
Review Editor
Molecular Medicine and Cancer Treatment
Umeå University
Umeå, Sweden
Review Editor
Molecular Medicine and Cancer Treatment
Cardiff University
Cardiff, United Kingdom
Review Editor
Molecular Medicine and Cancer Treatment
Jiangsu Province Geriatric Hospital
Nanjing, China
Review Editor
Molecular Medicine and Cancer Treatment
Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
Okayama, Japan
Review Editor
Molecular Medicine and Cancer Treatment
Swansea University Medical School
Swansea, United Kingdom
Review Editor
Molecular Medicine and Cancer Treatment
Gandhi Institute of Technology and Management (GITAM)
Visakhapatnam, India
Review Editor
Molecular Medicine and Cancer Treatment
KIIT University
Bhubaneswar, India
Review Editor
Molecular Medicine and Cancer Treatment
Morehouse School of Medicine
Atlanta, United States
Review Editor
Molecular Medicine and Cancer Treatment
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Review Editor
Molecular Medicine and Cancer Treatment
LSU Health Sciences Center New Orleans, Louisiana State University
New Orleans, United States
Review Editor
Molecular Medicine and Cancer Treatment